Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlejpicarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="ja"/>
<identifier>
<system value="https://www.pmda.jp/"/>
<value value="jpiplaceholder"/>
</identifier>
<type value="document"/>
<timestamp value="2002-08-01T13:28:17Z"/>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/Composition/carbamazepine200jpi"/>
<resource>
<Composition>
<id value="carbamazepine200jpi"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="ja"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="ja" lang="ja"><a name="Composition_carbamazepine200jpi"> </a><p><b>Generated Narrative: Composition</b><a name="carbamazepine200jpi"> </a><a name="hccarbamazepine200jpi"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceComposition "carbamazepine200jpi" (Language "ja") </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/rmswi/</code>/fcats34placeholder</p><p><b>status</b>: final</p><p><b>type</b>: Package Leaflet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#100000155538)</span></p><p><b>date</b>: 2002-08-01 13:28:17+0000</p><p><b>author</b>: See on this page: Organization/orgfujinaga</p><p><b>title</b>: Tegretol (carbamazepine) 200 mg for tablet</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td>Official <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-composition-attestation-mode.html">Composition Attestation Mode</a>#official)</span></td><td>2002-08-01 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<value value="fcats34placeholder"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<subject>
<reference
value="MedicinalProductDefinition/medprodcarbamazepine200"/>
</subject>
<date value="2002-08-01T13:28:17Z"/>
<author>
<reference value="Organization/orgfujinaga"/>
</author>
<title value="Tegretol (carbamazepine) 200 mg for tablet"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2002-08-01T13:28:17Z"/>
</attester>
<section>
<title value="アロマターゼ阻害剤/閉経後乳癌治療剤"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="0"/>
</coding>
<text value="アロマターゼ阻害剤/閉経後乳癌治療剤"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="1. 警告"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="1"/>
</coding>
<text value="1. 警告"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="1.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2.1"/>
</coding>
<text value="1.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="1.2"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2.1"/>
</coding>
<text value="1.2"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="1.3"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2.1"/>
</coding>
<text value="1.3"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="2. 禁忌(次の患者には投与しないこと)"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2"/>
</coding>
<text value="禁忌(次の患者には投与しないこと)"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="2.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2.1"/>
</coding>
<text value="2.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="2.2"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2.2"/>
</coding>
<text value="2.2"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="2.3"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="2.3"/>
</coding>
<text value="2.3"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="3. 組成・性状"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="3"/>
</coding>
<text value="3. 組成・性状"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="3.1 組成"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="3.1"/>
</coding>
<text value="3.1 組成"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="3.2 製剤の性状"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="3.2"/>
</coding>
<text value="3.2 製剤の性状"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="4. 効能又は効果"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="4"/>
</coding>
<text value="効能又は効果"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="5. 効能又は効果に関連する注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="5"/>
</coding>
<text value="効能又は効果に関連する注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="6. 用法及び用量"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="6"/>
</coding>
<text value="用法及び用量"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="7. 用法及び用量に関連する注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="7"/>
</coding>
<text value="7. 用法及び用量に関連する注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="8. 重要な基本的注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="8"/>
</coding>
<text value="重要な基本的注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="8.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="8.1"/>
</coding>
<text value="8.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="8.2"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="8.2"/>
</coding>
<text value="8.2"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="8.3"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="8.3"/>
</coding>
<text value="8.3"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="8.4"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="8.4"/>
</coding>
<text value="8.4"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="9. 特定の背景を有する患者に関する注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="特定の背景を有する患者に関する注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="9.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9.2"/>
</coding>
<text value="9.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="9.2 腎機能障害患者"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9.2"/>
</coding>
<text value="9.2 腎機能障害患者"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="9.2.1 重度の腎障害のある患者"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="9.2.1 重度の腎障害のある患者"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="9.3 肝機能障害患者"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9.3"/>
</coding>
<text value="9.3 肝機能障害患者"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="9.3.1 重度の肝障害のある患者"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9.3.1"/>
</coding>
<text value="9.3.1 重度の肝障害のある患者"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="9.4"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9.4"/>
</coding>
<text value="9.4"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="9.5 妊婦"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="9.5 妊婦"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="9.6 授乳婦"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9.6"/>
</coding>
<text value="9.6 授乳婦"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="10. 相互作用"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="10"/>
</coding>
<text value="10. 相互作用"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="10.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="10.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="10.2 併用注意(併用に注意すること)"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="10"/>
</coding>
<text value="10.2 併用注意(併用に注意すること)"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="11. 副作用"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="11"/>
</coding>
<text value="11. 副作用"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="11.1 重大な副作用"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="11.1"/>
</coding>
<text value="11.1 重大な副作用"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="11.1.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="11.1.1"/>
</coding>
<text value="11.1.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="11.2 その他の副作用"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="11.2"/>
</coding>
<text value="11.2 その他の副作用"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="12. 臨床検査結果に及ぼす影響"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="12"/>
</coding>
<text value="12. 臨床検査結果に及ぼす影響"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="13. 過量投与"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="13. 過量投与"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="14. 適用上の注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="14"/>
</coding>
<text value="14. 適用上の注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="14.1 薬剤交付時の注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="14.1"/>
</coding>
<text value="14.1 薬剤交付時の注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="15. その他の注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="15. その他の注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="15.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="15.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="15.2 非臨床試験に基づく情報"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="15.2 非臨床試験に基づく情報"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="16. 薬物動態"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16. 薬物動態"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="16.1 血中濃度"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.1 血中濃度"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="16.2 吸収"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.2 吸収"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="16.2.1 食事の影響"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.2.1 食事の影響"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="16.3 分布"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.3 分布"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="16.3.1 組織内濃度"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.3.1 組織内濃度"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="16.3.2 胎児・胎盤移行性"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.3.2 胎児・胎盤移行性"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="16.3.3 蛋白結合率"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.3.3 蛋白結合率"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="16.5 排泄"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.5 排泄"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="16.5.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.5.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="16.5.2"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.5.2"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="16.6 特定の背景を有する患者"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.6 特定の背景を有する患者"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="16.6.1 腎機能障害患者における体内動態"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.6.1 腎機能障害患者における体内動態"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="16.6.2 肝機能障害患者における体内動態"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="16.6.2 肝機能障害患者における体内動態"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
</section>
<section>
<title value="17. 臨床成績"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="17. 臨床成績"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="17.1 有効性及び安全性に関する試験"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="17.1 有効性及び安全性に関する試験"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="17.1.1 国内臨床試験"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="17.1.1 国内臨床試験"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="17.1.2 ブリッジング試験"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="17.1.2 ブリッジング試験"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="17.1.3 海外臨床試験(第III相試験)"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="17.1.3 海外臨床試験(第III相試験)"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="17.1.4 海外大規模比較試験(第III相試験 術後補助療法)"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="17.1.4 海外大規模比較試験(第III相試験 術後補助療法)"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="17.1.5 海外比較試験(術後補助療法)"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="13"/>
</coding>
<text value="17.1.5 海外比較試験(術後補助療法)"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title
value="17.1.6 非盲検無作為化比較試験(第II/III相試験 転移性乳癌に対する第一次 ホルモン療法)"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="16"/>
</coding>
<text
value="17.1.6 非盲検無作為化比較試験(第II/III相試験 転移性乳癌に対する第一次 ホルモン療法)"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
</section>
<section>
<title value="18. 薬効薬理"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="18"/>
</coding>
<text value="18. 薬効薬理"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="18.1 作用機序"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="18.1 作用機序"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="18.1.1 アロマターゼ阻害作用"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="18.1.1 アロマターゼ阻害作用"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
<section>
<title value="18.2 抗腫瘍効果"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="18.2 抗腫瘍効果"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="18.3 エストロゲン抑制作用"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="18.3 エストロゲン抑制作用"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<section>
<title value="18.3.1"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="18.3.1"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="18.3.2"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="17"/>
</coding>
<text value="18.3.2"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</section>
</section>
<section>
<title value="19. 有効成分に関する理化学的知見"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="19"/>
</coding>
<text value="19. 有効成分に関する理化学的知見"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="20. 取扱い上の注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="20. 取扱い上の注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="21. 承認条件"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="21. 承認条件"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="22. 包装"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="22"/>
</coding>
<text value="22. 包装"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="23. 主要文献"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="23"/>
</coding>
<text value="23. 主要文献"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="24. 文献請求先及び問い合わせ先"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="24"/>
</coding>
<text value="24. 文献請求先及び問い合わせ先"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="25. 保険給付上の注意"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="9"/>
</coding>
<text value="25. 保険給付上の注意"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="26. 製造販売業者等"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="26"/>
</coding>
<text value="26. 製造販売業者等"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
<section>
<title value="26.1 製造販売元"/>
<code>
<coding>
<system value="https://pmda.jp/"/>
<code value="26"/>
</coding>
<text value="26.1 製造販売元"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/Organization/orgfujinaga"/>
<resource>
<Organization>
<id value="orgfujinaga"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="Organization_orgfujinaga"> </a><p><b>Generated Narrative: Organization</b><a name="orgfujinaga"> </a><a name="hcorgfujinaga"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceOrganization "orgfujinaga" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Organization-uv-epi.html">Organization (ePI)</a></p></div><p><b>identifier</b>: <code>https://pmda-org-id</code>/fujinaga (use: official)</p><p><b>active</b>: true</p><p><b>type</b>: Marketing authorisation holder <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#tbd)</span></p><p><b>name</b>: Fujinaga Pharmaceutical Co., Ltd.</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Address</b></td></tr><tr><td style="display: none">*</td><td>Medicine Consultation Office Front Place Nihonbashi 2-14-1 Nihonbashi, Chuo-ku,(work)</td></tr></table></div>
</text>
<identifier>
<use value="official"/>
<system value="https://pmda-org-id"/>
<value value="fujinaga"/>
</identifier>
<active value="true"/>
<type>
<coding>
<system value="https://PMDA-org-type.jp/"/>
<code value="tbd"/>
<display value="Marketing authorisation holder"/>
</coding>
<text value="Marketing authorisation holder"/>
</type>
<name value="Fujinaga Pharmaceutical Co., Ltd."/>
<contact>
<address>
<use value="work"/>
<type value="physical"/>
<text
value="Medicine Consultation Office Front Place Nihonbashi 2-14-1 Nihonbashi, Chuo-ku,"/>
<line value="2-14-1 Nihonbashi"/>
<city value="Chuo-ku"/>
<postalCode value="103-8324"/>
<country value="Tokyo"/>
</address>
</contact>
</Organization>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/Authorizations/authcarbamazepine200"/>
<resource>
<RegulatedAuthorization>
<id value="authcarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="RegulatedAuthorization_authcarbamazepine200"> </a><p><b>Generated Narrative: RegulatedAuthorization</b><a name="authcarbamazepine200"> </a><a name="hcauthcarbamazepine200"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceRegulatedAuthorization "authcarbamazepine200" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-RegulatedAuthorization-uv-epi.html">RegulatedAuthorization (ePI)</a></p></div><p><b>identifier</b>: <code>https://pmda-approvalandlicenseno/</code>/22700AMX00173 (use: official)</p><p><b>subject</b>: See on this page: MedicinalProductDefinition/medprodcarbamazepine200</p><p><b>type</b>: Marketing Authorisation <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#100000072062)</span></p><p><b>region</b>: Japan <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#JP)</span></p><p><b>status</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2002-08-01 13:28:17+0000</p><p><b>holder</b>: See on this page: Organization/orgfujinaga</p></div>
</text>
<identifier>
<use value="official"/>
<system value="https://pmda-approvalandlicenseno/"/>
<value value="22700AMX00173"/>
</identifier>
<subject>
<reference
value="MedicinalProductDefinition/medprodcarbamazepine200"/>
</subject>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="/#100000072062"/>
</coding>
<text value="Marketing Authorisation"/>
</type>
<region>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="JP"/>
</coding>
<text value="Japan"/>
</region>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
</coding>
<text value="Active"/>
</status>
<statusDate value="2002-08-01T13:28:17Z"/>
<holder>
<reference value="Organization/orgfujinaga"/>
</holder>
</RegulatedAuthorization>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/MedicinalProductDefinition/medprodcarbamazepine200"/>
<resource>
<MedicinalProductDefinition>
<id value="medprodcarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_medprodcarbamazepine200"> </a><p><b>Generated Narrative: MedicinalProductDefinition</b><a name="medprodcarbamazepine200"> </a><a name="hcmedprodcarbamazepine200"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceMedicinalProductDefinition "medprodcarbamazepine200" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-MedicinalProductDefinition-uv-epi.html">MedicinalProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>http://iyaku.info/medicine</code>/1139002F1070</p><p><b>type</b>: Medicinal Product <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-medicinal-product-type.html">Medicinal Product Type</a>#MedicinalProduct)</span></p><p><b>domain</b>: Human use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-medicinal-product-domain.html">Medicinal Product Domain</a>#Human)</span></p><p><b>status</b>: active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072084)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Tegretol (carbamazepine) 200 mg for tablet</p><p><b>type</b>: Full name <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000001)</span></p><blockquote><p><b>part</b></p><p><b>part</b>: Tegretol</p><p><b>type</b>: Invented name part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000002)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: carbamazepine</p><p><b>type</b>: Scientific name part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000003)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: 200 mg</p><p><b>type</b>: Strength part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000004)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: tablet</p><p><b>type</b>: Pharmaceutical dose form part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000005)</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td>Japan <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#JP)</span></td><td>Japan <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#JP)</span></td><td>Japanese (Region=Japan) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#ja-JP)</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://iyaku.info/medicine"/>
<value value="1139002F1070"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Tegretol (carbamazepine) 200 mg for tablet"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
</coding>
<text value="Full name"/>
</type>
<part>
<part value="Tegretol"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
</coding>
<text value="Invented name part"/>
</type>
</part>
<part>
<part value="carbamazepine"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
</coding>
<text value="Scientific name part"/>
</type>
</part>
<part>
<part value="200 mg"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
</coding>
<text value="Strength part"/>
</type>
</part>
<part>
<part value="tablet"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
</coding>
<text value="Pharmaceutical dose form part"/>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="JP"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="JP"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="ja-JP"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/packcarbamazepine200"/>
<resource>
<PackagedProductDefinition>
<id value="packcarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="PackagedProductDefinition_packcarbamazepine200"> </a><p><b>Generated Narrative: PackagedProductDefinition</b><a name="packcarbamazepine200"> </a><a name="hcpackcarbamazepine200"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourcePackagedProductDefinition "packcarbamazepine200" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-PackagedProductDefinition-uv-epi.html">PackagedProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://pmda-packinsertno/</code>/placeholder2 (use: official)</p><p><b>name</b>: Tegretol (carbamazepine) 200 mg for tablet in bottles</p><p><b>type</b>: Chemical Medininal Prodcut <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000155527)</span></p><p><b>packageFor</b>: See on this page: MedicinalProductDefinition/medprodcarbamazepine200</p><p><b>status</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2002-08-01 13:28:17+0000</p><p><b>containedItemQuantity</b>: 200 mg</p><p><b>manufacturer</b>: See on this page: Organization/orgfujinaga</p><h3>Packagings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Identifier</b></td><td><b>Type</b></td><td><b>Quantity</b></td><td><b>Material</b></td></tr><tr><td style="display: none">*</td><td><code>https://spor.ema.europa.eu/pmswi</code>/123456</td><td>Bottle <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073497)</span></td><td>28</td><td>PolyVinyl Chloride <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000003222)</span></td></tr></table></div>
</text>
<identifier>
<use value="official"/>
<system value="https://pmda-packinsertno/"/>
<value value="placeholder2"/>
</identifier>
<name value="Tegretol (carbamazepine) 200 mg for tablet in bottles"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000155527"/>
<display value="Chemical Medininal Prodcut"/>
</coding>
</type>
<packageFor>
<reference
value="MedicinalProductDefinition/medprodcarbamazepine200"/>
</packageFor>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="Active"/>
</coding>
</status>
<statusDate value="2002-08-01T13:28:17Z"/>
<containedItemQuantity>
<value value="200"/>
<unit value="mg"/>
</containedItemQuantity>
<manufacturer>
<reference value="Organization/orgfujinaga"/>
</manufacturer>
<packaging>
<identifier>
<system value="https://spor.ema.europa.eu/pmswi"/>
<value value="123456"/>
</identifier>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000073497"/>
<display value="Bottle"/>
</coding>
</type>
<quantity value="28"/>
<material>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="200000003222"/>
<display value="PolyVinyl Chloride"/>
</coding>
</material>
</packaging>
</PackagedProductDefinition>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/adminprodcarbamazepine200"/>
<resource>
<AdministrableProductDefinition>
<id value="adminprodcarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="AdministrableProductDefinition_adminprodcarbamazepine200"> </a><p><b>Generated Narrative: AdministrableProductDefinition</b><a name="adminprodcarbamazepine200"> </a><a name="hcadminprodcarbamazepine200"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceAdministrableProductDefinition "adminprodcarbamazepine200" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-AdministrableProductDefinition-uv-epi.html">AdministrableProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://www.who-umc.org/phpid</code>/FB9808F4FED210183F412F9998622287</p><p><b>status</b>: active</p><p><b>formOf</b>: See on this page: MedicinalProductDefinition/medprodcarbamazepine200</p><p><b>administrableDoseForm</b>: Tablet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#10219000)</span></p><p><b>unitOfPresentation</b>: 15054000 <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#15054000)</span></p><p><b>producedFrom</b>: See on this page: ManufacturedItemDefinition/manitemcarbamazepine200</p><h3>RouteOfAdministrations</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td></tr><tr><td style="display: none">*</td><td>20053000 <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#20053000)</span></td></tr></table></div>
</text>
<identifier>
<system value="https://www.who-umc.org/phpid"/>
<value value="FB9808F4FED210183F412F9998622287"/>
</identifier>
<status value="active"/>
<formOf>
<reference
value="MedicinalProductDefinition/medprodcarbamazepine200"/>
</formOf>
<administrableDoseForm>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="10219000"/>
</coding>
<text value="Tablet"/>
</administrableDoseForm>
<unitOfPresentation>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="15054000"/>
</coding>
</unitOfPresentation>
<producedFrom>
<reference
value="ManufacturedItemDefinition/manitemcarbamazepine200"/>
</producedFrom>
<routeOfAdministration>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="20053000"/>
</coding>
</code>
</routeOfAdministration>
</AdministrableProductDefinition>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/manitemcarbamazepine200"/>
<resource>
<ManufacturedItemDefinition>
<id value="manitemcarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="ManufacturedItemDefinition_manitemcarbamazepine200"> </a><p><b>Generated Narrative: ManufacturedItemDefinition</b><a name="manitemcarbamazepine200"> </a><a name="hcmanitemcarbamazepine200"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceManufacturedItemDefinition "manitemcarbamazepine200" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-ManufacturedItemDefinition-uv-epi.html">ManufacturedItemDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://pmda-sccj</code>/placeholder (use: official)</p><p><b>status</b>: active</p><p><b>manufacturedDoseForm</b>: Tablet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#10219000)</span></p><p><b>unitOfPresentation</b>: 15054000 <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#15054000)</span></p><p><b>manufacturer</b>: See on this page: Organization/orgfujinaga</p></div>
</text>
<identifier>
<use value="official"/>
<system value="https://pmda-sccj"/>
<value value="placeholder"/>
</identifier>
<status value="active"/>
<manufacturedDoseForm>
<coding>
<system
value="https://standardterms.edqm.eu/browse/get_concepts_by/SOM/SOM/"/>
<code value="10219000"/>
</coding>
<text value="Tablet"/>
</manufacturedDoseForm>
<unitOfPresentation>
<coding>
<system
value="https://standardterms.edqm.eu/browse/get_concepts/UOP/"/>
<code value="15054000"/>
</coding>
</unitOfPresentation>
<manufacturer>
<reference value="Organization/orgfujinaga"/>
</manufacturer>
</ManufacturedItemDefinition>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/carbamazepine"/>
<resource>
<Ingredient>
<id value="carbamazepine"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="Ingredient_carbamazepine"> </a><p><b>Generated Narrative: Ingredient</b><a name="carbamazepine"> </a><a name="hccarbamazepine"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceIngredient "carbamazepine" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta/</code>/33CM23913M (use: official)</p><p><b>status</b>: active</p><p><b>for</b>: See on this page: ManufacturedItemDefinition/manitemcarbamazepine200</p><p><b>role</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072072)</span></p><h3>Manufacturers</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Manufacturer</b></td></tr><tr><td style="display: none">*</td><td>See on this page: Organization/orgfujinaga</td></tr></table><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>carbamazepine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#33CM23913M)</span></td></tr></table><h3>Strengths</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style="display: none">*</td><td>200 mg</td><td>active ingredient - basis of strength <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-RoleClass.html">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>
</text>
<identifier>
<use value="official"/>
<system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
<value value="33CM23913M"/>
</identifier>
<status value="active"/>
<for>
<reference
value="ManufacturedItemDefinition/manitemcarbamazepine200"/>
</for>
<role>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072072"/>
<display value="Active"/>
</coding>
</role>
<manufacturer>
<manufacturer>
<reference value="Organization/orgfujinaga"/>
</manufacturer>
</manufacturer>
<substance>
<code>
<concept>
<coding>
<system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
<code value="33CM23913M"/>
<display value="carbamazepine"/>
</coding>
</concept>
</code>
<strength>
<presentationQuantity>
<value value="200"/>
<unit value="mg"/>
</presentationQuantity>
<basis>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
<code value="ACTIB"/>
</coding>
<text value="active ingredient - basis of strength"/>
</basis>
</strength>
</substance>
</Ingredient>
</resource>
</entry>
<entry>
<fullUrl
value="http://hl7.eu/fhir/ig/gravitate-health/SubstanceDefinition/subcarbamazepine200"/>
<resource>
<SubstanceDefinition>
<id value="subcarbamazepine200"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="SubstanceDefinition_subcarbamazepine200"> </a><p><b>Generated Narrative: SubstanceDefinition</b><a name="subcarbamazepine200"> </a><a name="hcsubcarbamazepine200"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceSubstanceDefinition "subcarbamazepine200" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-SubstanceDefinition-uv-epi.html">SubstanceDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta/</code>/33CM23913M (use: official)</p><p><b>version</b>: 39</p><p><b>status</b>: Validated (UNII) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#1)</span></p><p><b>description</b>: White to pale yellow</p><p><b>manufacturer</b>: See on this page: Organization/orgfujinaga</p><h3>Structures</h3><table class="grid"><tr><td style="display: none">-</td><td><b>MolecularFormula</b></td></tr><tr><td style="display: none">*</td><td>C15H12N2O</td></tr></table><h3>Names</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Name</b></td><td><b>Type</b></td></tr><tr><td style="display: none">*</td><td>carbamazepine</td><td>Chemical Name <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#1)</span></td></tr></table></div>
</text>
<identifier>
<use value="official"/>
<system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
<value value="33CM23913M"/>
</identifier>
<version value="39"/>
<status>
<coding>
<system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
<code value="1"/>
</coding>
<text value="Validated (UNII)"/>
</status>
<description value="White to pale yellow"/>
<manufacturer>
<reference value="Organization/orgfujinaga"/>
</manufacturer>
<structure>
<molecularFormula value="C15H12N2O"/>
</structure>
<name>
<name value="carbamazepine"/>
<type>
<coding>
<system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
<code value="1"/>
</coding>
<text value="Chemical Name"/>
</type>
</name>
</SubstanceDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.gh#0.1.0 based on FHIR 5.0.0. Generated 2024-05-15
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
